Recent studies show that the metalloproteinases are also associated with poorer relapse-free survival in HER2+ BC patients and the inhibition of metalloproteinases by chemicals overcame trastuzumab resistance in both naïve and trastuzumab-resistant HER2+ cell lines [131,132,133]. Here, ERBB2 is linked to breast cancer.